Search Results - "Cattrini, Carlo"

Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer by Lozano, Rebeca, Castro, Elena, Aragón, Isabel M., Cendón, Ylenia, Cattrini, Carlo, López-Casas, Pedro P., Olmos, David

“…Over the past years, several studies have demonstrated that defects in DNA damage response and repair (DDR) genes are present in a significant proportion of…”
Get full text

CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials by Messina, Carlo, Cattrini, Carlo, Buzzatti, Giulia, Cerbone, Luigi, Zanardi, Elisa, Messina, Marco, Boccardo, Francesco

“…Purpose Combining CDK4/6 inhibitors and endocrine therapy (ET) improved outcomes for the treatment of metastatic HR+/HER2− breast cancers. Here, we performed a…”
Get full text

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications by Zanardi, Elisa, Boccardo, Francesco, Castro, Elena, Caffo, Orazio, Vallome, Giacomo, Soldato, Davide, Cattrini, Carlo, Messina, Carlo, Olmos, David

“…Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant…”
Get full text

Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients by Cattrini, Carlo, Manfredi, Marcello, Barboro, Paola, Ghirimoldi, Marco, Mennitto, Alessia, Martini, Veronica, Battioni, Alessio, Le Van, Marco, Gobbato, Simone, Branni, Carmen, Ayed, Rahma Ben, Pinato, David James, Catalano, Fabio, Zanardi, Elisa, Boccardo, Francesco, Gennari, Alessandra

“…Emerging evidence highlights the potential prognostic relevance of circulating lipids in metastatic castration-resistant prostate cancer (mCRPC), with a…”
Get full text

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis by Cattrini, Carlo, Messina, Carlo, Airoldi, Chiara, Buti, Sebastiano, Roviello, Giandomenico, Mennitto, Alessia, Caffo, Orazio, Gennari, Alessandra, Bersanelli, Melissa

“…Background: In recent years, new therapeutic combinations based on immunotherapy provided significant benefits as a first-line treatment for patients with…”
Get full text

A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer by Capaia, Matteo, Granata, Ilaria, Guarracino, Mario, Petretto, Andrea, Inglese, Elvira, Cattrini, Carlo, Ferrari, Nicoletta, Boccardo, Francesco, Barboro, Paola

“…The major challenge in castration-resistant prostate cancer (CRPC) remains the ability to predict the clinical responses to improve patient selection for…”
Get full text

Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty? by Barranco, Rosario, Messina, Carlo, Bonsignore, Alessandro, Cattrini, Carlo, Ventura, Francesco

“…The COVID-19 outbreak rapidly became a public health emergency affecting particularly the frail category as cancer patients. This led oncologists to radical…”
Get full text

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone by Zanardi, Elisa, Soldato, Davide, Latocca, Maria Maddalena, Cattrini, Carlo, Boccardo, Francesco

“…The recently published phase II prospective SWITCH trial evaluated whether patients with metastatic castration-resistant prostate cancer (mCRPC) treated with…”
Get full text

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study by Tommasi, Chiara, Scartabellati, Giulia, Giannarelli, Diana, Giorgi, Ugo De, Brighi, Nicole, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Puglisi, Silvia, Caffo, Orazio, Kinspergher, Stefania, Mennitto, Alessia, Cattrini, Carlo, Santoni, Matteo, Verzoni, Elena, Rametta, Alessandro, Stellato, Marco, Malgeri, Andrea, Roviello, Giandomenico, Brunelli, Matteo, Buti, Sebastiano

“…Background: Tyrosine-kinase inhibitors (TKIs) and immunotherapy represent the backbone treatment for metastatic renal cell carcinoma (mRCC) patients. The aim…”
Get full text

Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer by Cattrini, Carlo, Barboro, Paola, Rubagotti, Alessandra, Zinoli, Linda, Zanardi, Elisa, Capaia, Matteo, Boccardo, Francesco

“…Periostin (POSTN) is an extracellular matrix protein associated with tumor progression and shorter survival in prostate cancer (PCa). Here, we performed an…”
Get full text

Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer by Lorente, David, Castro, Elena, Lozano, Rebeca, Puente, Javier, Romero-Laorden, Nuria, Rodríguez-Vida, Alejo, Lainez, Nuria, Villatoro, Rosa, Llácer, Casilda, Cattrini, Carlo, Hernández, Amaia, Domenech, Montserrat, Zambrana, Francisco, Almagro, Elena, Luque, Raquel, Martinez, Esther, López-Campos, Fernando, Gonzalez, Belen, Méndez-Vidal, Maria Jose, Medina, Ana, Piulats, Josep Maria, Olmos, David

Get full text

Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights by Biello, Federica, Platini, Francesca, D'Avanzo, Francesca, Cattrini, Carlo, Mennitto, Alessia, Genestroni, Silvia, Martini, Veronica, Marzullo, Paolo, Aimaretti, Gianluca, Gennari, Alessandra

“…Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism…”
Get full text

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? by Roviello, Giandomenico, Buti, Sebastiano, Cattrini, Carlo, Mennitto, Alessia, Messina, Carlo, Airoldi, Chiara, Vannini, Gianmarco, Bersanelli, Melissa

Get full text

Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study by Provinciali, Nicoletta, Piccininno, Marco, Siri, Giacomo, Gennari, Alessandra, Antonucci, Giancarlo, Ricci, Damiano, Devoto, Emmanuela, Miceli, Roberta, Cortesi, Pietro, Pazzi, Chiara, Nanni, Oriana, Mannozzi, Francesca, Pastina, Ilaria, Messuti, Luciana, Bengala, Carmelo, Frassineti, Giovanni Luca, Cattrini, Carlo, Fava, Marianna, Buttiron Webber, Tania, Briata, Irene Maria, Corradengo, Davide, DeCensi, Andrea, Puntoni, Matteo

“…Serum biomarkers have been investigated as predictive risk factors for cancer-related cardiovascular (CV) risk, but their analysis is limited to their baseline…”
Get full text

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score by Mazzaschi, Giulia, Lazzarin, Alessandro, Santoni, Matteo, Trentini, Francesca, Giorgi, Ugo De, Brighi, Nicole, Tommasi, Chiara, Puglisi, Silvia, Caffo, Orazio, Kinspergher, Stefania, Mennitto, Alessia, Cattrini, Carlo, Verzoni, Elena, Rametta, Alessandro, Stellato, Marco, Malgeri, Andrea, Roviello, Giandomenico, Silini, Enrico Maria, Rescigno, Pasquale, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Quaini, Federico, Giudice, Giulia Claire, Banna, Giuseppe Luigi, Buti, Sebastiano

“…BACKGROUNDThe advent of immune checkpoint inhibitors (ICIs) has revolutionized the metastatic renal cell carcinoma (mRCC) therapeutic landscape. Nevertheless,…”
Get full text

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study by Cattrini, Carlo, Capaia, Matteo, Boccardo, Francesco, Barboro, Paola

“…•Etoposide is a chemotherapeutic agent that shows significant activity in preclinical models of prostate cancer and increased activity is observed in the most…”
Get full text

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes by Cavo, Alessia, Rubagotti, Alessandra, Zanardi, Elisa, Fabbroni, Chiara, Zinoli, Linda, Di Meglio, Antonio, Arboscello, Eleonora, Bellodi, Andrea, Spallarossa, Paolo, Cattrini, Carlo, Messina, Carlo, Boccardo, Francesco

“…Background: The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and…”
Get full text

Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients by Buti, Sebastiano, Olivari, Alessandro, Masini, Cristina, Bimbatti, Davide, Sartori, Donata, Ermacora, Paola, Cattrini, Carlo, Vitale, Maria Giuseppa, Rossi, Ernesto, Mucciarini, Claudia, Rizzo, Mimma, Sisani, Michele, Santoni, Matteo, Roviello, Giandomenico, Mollica, Veronica, Conteduca, Vincenza, Grillone, Francesco, Cinausero, Marika, Prati, Giuseppe, Atzori, Francesco, Stellato, Marco, Massari, Francesco, Bersanelli, Melissa

“…The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. The primary…”
Get full text

GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak by Bersanelli, Melissa, Buti, Sebastiano, Rizzo, Mimma, Cortellini, Alessio, Cattrini, Carlo, Massari, Francesco, Masini, Cristina, Vitale, Maria Giuseppa, Fornarini, Giuseppe, Caffo, Orazio, Atzori, Francesco, Gatti, Alice, Macrini, Serena, Mucciarini, Claudia, Galli, Luca, Morelli, Franco, Stellato, Marco, Fanelli, Martina, Corti, Francesca, Zucali, Paolo Andrea, Toscani, Ilaria, Dalla Volta, Alberto, Gernone, Angela, Baldessari, Cinzia, La Torre, Leonardo, Zara, Diego, Gennari, Alessandra, Bracarda, Sergio, Procopio, Giuseppe, Porta, Camillo

“…Background: Considering the growing genitourinary (GU) cancer population undergoing systemic treatment with immune checkpoint inhibitors (ICIs) in the context…”
Get full text

Atezolizumab and bladder cancer: facing a complex disease by Cattrini, Carlo, Boccardo, Francesco

“…In 2016, Rosenberg and colleagues published the results of this programmed death ligand 1 (PD-L1) inhibitor in patients who had previously received…”
Get full text